Haptoglobin Administration for Intravascular Hemolysis: A Systematic Review

Area of Science:

• Hematology
• Nephrology
• Pharmacology

Background:

• Hemolysis can lead to organ damage due to elevated plasma-free hemoglobin (pfHb).
• Haptoglobin, a plasma protein, plays a role in clearing free hemoglobin.
• This review examines the efficacy and safety of exogenous haptoglobin administration for treating hemolysis.

Approach:

• Systematic review and quantitative synthesis of 13 studies involving 677 patients.
• Included studies compared haptoglobin treatment against control groups for hemolysis-related complications.
• Primary outcome was the change in pfHb concentration 1 hour post-infusion.

Key Points:

• Haptoglobin administration significantly reduced pfHb levels at 1 and 24 hours post-infusion.
• A lower incidence of acute kidney injury was observed in patients treated with haptoglobin.
• No significant difference in all-cause mortality was found between treatment and control groups.

Conclusions:

• Exogenous haptoglobin is effective in reducing pfHb levels during hemolysis.
• Haptoglobin administration may preserve kidney function in patients with hemolysis.
• Haptoglobin treatment appears safe, with no reported adverse events or increased mortality.